The blinq screening device directly detected amblyopia and strabismus with high sensitivity in pediatric patients, according to a study published in the American Journal of Ophthalmology.
“Most vision screening devices are designed to detect amblyopia risk factors (ARFs), including strabismus and refractive error abnormalities most associated with the development of amblyopia,” study author Savannah Reaves Monahan, BS, from the Storm Eye Institute at the Medical University of South Carolina, and colleagues wrote. “The blinq is a new screening device designed to directly detect amblyopia and strabismus rather than ARFs.”
In a prospective, clinical validity analysis of the blinq (Rebion Inc.), 267 children (average age, 6.3 years; 54.7% girls) underwent screening to detect amblyopia or strabismus first with the device and then with a pediatric ophthalmologist, who was masked to the blinq results. The blinq results were delivered as pass or refer.
Comparing the screening results, the researchers reported that the blinq detected amblyopia or any constant strabismus with a sensitivity of 87.5% and specificity of 51.3%. When including children with intermittent strabismus and/or high refractive error, which had been referred by the blinq, the device had an improved sensitivity of 91.3% and specificity of 63.2%.
“The blinq offers a sensitive screening device for direct detection of amblyopia and strabismus,” Monahan and colleagues wrote. “We present our results to continue to inform care providers and communities as they design programs to improve children’s vision.”